Polymorphic forms of rifaximin and clinical efficacy
Drug profileGastroent Hepatol 2025; 79(2): 131–133. doi: 10.48095/ccgh2025131
Literaturepdf Milan LukášUpdate on screening for latent tuberculosis in patients on biological therapy
Diskuzní příspěvekGastroent Hepatol 2025; 79(2): 134–135. doi: 10.48095/ccgh2025134
Literaturepdf Milan LukášIron carboxymaltose in the treatment of iron deficiency/anaemia in patients with IBD
Drug profileGastroent Hepatol 2025; 79(1): 58–64. doi: 10.48095/ccgh202558
Literaturepdf Michaela BachratáBiosimilar ustekinumab CT-P43
Drug profileGastroent Hepatol 2025; 79(1): 55–56. doi: 10.48095/ccgh202555
Literaturepdf Milan LukášResults of the DIPEX project on Crohn‘s disease and ulcerative colitis
Review articleGastroent Hepatol 2025; 79(1): 43–48. doi: 10.48095/ccgh202543
SummaryLiteraturepdf Hana Bednaříková, Kristýna GábováMirikizumab in patients with ulcerative colitis – cases from clinical practice
Gastroent Hepatol 2025; 79(1): 37–42. doi: 10.48095/ccgh202537
SummaryLiterature Milan Lukáš, Dominik Bettenworth, Viktorie ZacharováThe most common psychiatric disorders in patients with inflammatory bowel disease
Review articleGastroent Hepatol 2025; 79(1): 30–36. doi: 10.48095/ccgh202530
SummaryLiteraturepdf Petra Mináriková, Petra Matějková, Martina Hazuková, Martina PfeiferováCurrent problems in the care of patients with inflammatory bowel disease in the Czech Republic
Review articleGastroent Hepatol 2025; 79(1): 22–29. doi: 10.48095/ccgh202522
SummaryLiteraturepdf Martin Bortlík, Petra Matějková, Gleb DoninAssessment of intestinal involvement in patients with Crohn’s disease using the MaRIA scoring system
Original articleGastroent Hepatol 2025; 79(1): 14–21. doi: 10.48095/ccgh202514
SummaryLiteraturepdf Vlastimil Válek, Markéta Smělá, Marek Dostál, Štefan Konečný, Daniel Bartušek, Lucie Prokopová